Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) are commonly used as first-line therapeutics against various cancers (5, 8–10). The gene discussed is PDCD1; the disease is cancer.